Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Andrea, C.E. (Carlos Eduardo) de | - |
dc.creator | Perez-Gracia, J.L. (Jose Luis) | - |
dc.creator | Castañon, E. (Eduardo) | - |
dc.creator | Ponz-Sarvise, M. (Mariano) | - |
dc.creator | Echeveste, J.I. (José I.) | - |
dc.creator | Melero, I. (Ignacio) | - |
dc.creator | Fernandez-Sanmamed, M. (Miguel) | - |
dc.creator | Rodriguez-Ruiz, M.E. (María Esperanza) | - |
dc.date.accessioned | 2023-05-16T11:20:29Z | - |
dc.date.available | 2023-05-16T11:20:29Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Andrea, C.E. (Carlos Eduardo) de; Perez-Gracia, J.L. (Jose Luis); Castañon, E. (Eduardo); et al. "Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors". OncoImmunology. 9 (1), 2020, e1760676-1 - e1760676-5 | es |
dc.identifier.issn | 2162-402X | - |
dc.identifier.uri | https://hdl.handle.net/10171/66259 | - |
dc.description.abstract | Checkpoint inhibitors have improved the survival of patients with advanced tumors and show a manageable toxicity profile. However, auto-immune colitis remains a relevant side effect, and combinations of anti-PD1/PDL1 and anti-CTLA-4 increase its incidence and severity. Here, we report the case of a 50-year-old patient diagnosed with stage IV cervical cancer that relapsed following radical surgery, external radiation/brachytherapy and standard chemotherapy. She was subsequently treated with Nivolumab and Ipilimumab combination and developed grade 2 colitis presenting a dissociation between endoscopic and pathological findings. At cycle 10 the patient reported grade 3 diarrhea and abdominal discomfort, without blood or mucus in the stools. Immunotherapy was withheld and a colonoscopy was performed, showing normal mucosa in the entire colon. Puzzlingly, histologic evaluation of randomly sampled mucosal biopsy of the distal colon showed an intense intraepithelial lymphocyte infiltration with crypt loss and some regenerating crypts with a few apoptotic bodies set in a chronically inflamed lamina propria, consistent with the microscopic diagnosis of colitis. Treatment with methylprednisolone 2 mg/kg was initiated which led to a decrease in the number of stools to grade 1. Additional investigations to exclude other causes of diarrhea rendered negative results. The patient experienced a major partial response and, following the resolution of diarrhea, she was re-challenged again with immunotherapy, with the reappearance of grade 2 diarrhea, leading to permanent immunotherapy interruption. We conclude and propose that performing random colonic biopsies should be considered in cases of immune checkpoint-associated unexplained diarrhea, even when colonoscopy shows macroscopically normal colonic mucosa inflammatory lesions. | es_ES |
dc.description.sponsorship | This project has received funding from the European Union's Horizon 2020 research and innovation programme (grant agreement n° 635122 - PROCROP). M.E.R.R. is supported by a fellowship from CRIS/ FEOR Foundation Against Cancer 2017-2018. | es_ES |
dc.language.iso | eng | es_ES |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/635122/EU | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Colitis | es_ES |
dc.subject | Immune-related adverse event | es_ES |
dc.subject | Nivolumab | es_ES |
dc.subject | Ipilimumab | es_ES |
dc.title | Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. | es_ES |
dc.identifier.doi | 10.1080/2162402X.2020.1760676 | - |
dadun.citation.endingPage | e1760676-5 | es_ES |
dadun.citation.number | 1 | es_ES |
dadun.citation.publicationName | OncoImmunology | es_ES |
dadun.citation.startingPage | e1760676-1 | es_ES |
dadun.citation.volume | 9 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.